{"id":"https://openalex.org/W4389247648","doi":"https://doi.org/10.1182/blood-2023-186432","title":"Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase","display_name":"Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase","publication_year":2023,"publication_date":"2023-11-02","ids":{"openalex":"https://openalex.org/W4389247648","doi":"https://doi.org/10.1182/blood-2023-186432"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2023-186432","doi":"https://doi.org/10.1182/blood-2023-186432","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-186432","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014241029","display_name":"Jennifer Ann Woyach","orcid":"https://orcid.org/0000-0002-3403-9144","observed_orcids":["https://orcid.org/0000-0002-3403-9144"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer A. Woyach","raw_affiliation_strings":["1The Ohio State University Comprehensive Cancer Center, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1The Ohio State University Comprehensive Cancer Center, Columbus, OH","institution_ids":["https://openalex.org/I2799885155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031412066","display_name":"Deborah Marie Stephens","orcid":"https://orcid.org/0000-0001-9188-5008","observed_orcids":["https://orcid.org/0000-0001-9188-5008"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah M. Stephens","raw_affiliation_strings":["2Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Huntsman Cancer Institute, University of Utah, Salt Lake City, UT","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042332348","display_name":"Danielle M. Brander","orcid":"https://orcid.org/0000-0002-9581-2807","observed_orcids":["https://orcid.org/0000-0002-9581-2807"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]},{"id":"https://openalex.org/I4390039326","display_name":"Duke Cancer Institute","ror":"https://ror.org/04vt65461","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876","https://openalex.org/I4390039326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danielle M Brander","raw_affiliation_strings":["3Duke Cancer Center, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Duke Cancer Center, Durham, NC","institution_ids":["https://openalex.org/I4210126298","https://openalex.org/I4390039326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069318162","display_name":"Adam S. Kittai","orcid":"https://orcid.org/0000-0002-4891-6144","observed_orcids":["https://orcid.org/0000-0002-4891-6144"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam S Kittai","raw_affiliation_strings":["4Division of Hematology, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Division of Hematology, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024273516","display_name":"Boyu Hu","orcid":"https://orcid.org/0000-0001-9848-9497","observed_orcids":["https://orcid.org/0000-0001-9848-9497"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Boyu Hu","raw_affiliation_strings":["2Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Huntsman Cancer Institute, University of Utah, Salt Lake City, UT","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062061907","display_name":"Andrea Phillips Sitlinger","orcid":"https://orcid.org/0000-0002-2231-5527","observed_orcids":["https://orcid.org/0000-0002-2231-5527"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]},{"id":"https://openalex.org/I4390039326","display_name":"Duke Cancer Institute","ror":"https://ror.org/04vt65461","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876","https://openalex.org/I4390039326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrea Sitlinger","raw_affiliation_strings":["3Duke Cancer Center, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Duke Cancer Center, Durham, NC","institution_ids":["https://openalex.org/I4210126298","https://openalex.org/I4390039326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090729996","display_name":"Emily K. Curran","orcid":"https://orcid.org/0000-0001-8159-4733","observed_orcids":["https://orcid.org/0000-0001-8159-4733"]},"institutions":[{"id":"https://openalex.org/I63135867","display_name":"University of Cincinnati","ror":"https://ror.org/01e3m7079","country_code":"US","type":"education","lineage":["https://openalex.org/I63135867"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emily K Curran","raw_affiliation_strings":["5Hematology/Oncology, University of Cincinnati, Cincinnati, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Hematology/Oncology, University of Cincinnati, Cincinnati, OH","institution_ids":["https://openalex.org/I63135867"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032952436","display_name":"Fenlai Tan","orcid":"https://orcid.org/0009-0002-7289-3218","observed_orcids":["https://orcid.org/0009-0002-7289-3218"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fenlai Tan","raw_affiliation_strings":["6Guangzhou Lupeng Pharmaceutical Co. Ltd, Guangzhou, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Guangzhou Lupeng Pharmaceutical Co. Ltd, Guangzhou, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092272362","display_name":"Yi Chen","orcid":"https://orcid.org/0009-0005-0945-6930","observed_orcids":["https://orcid.org/0009-0005-0945-6930"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yi Chen","raw_affiliation_strings":["7Newave Pharmaceutical Inc., Pleasanton, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Newave Pharmaceutical Inc., Pleasanton, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029811877","display_name":"Stephen Patrick Anthony","orcid":"https://orcid.org/0009-0009-6005-5592","observed_orcids":["https://orcid.org/0009-0009-6005-5592"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephen P. Anthony","raw_affiliation_strings":["7Newave Pharmaceutical Inc., Pleasanton, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Newave Pharmaceutical Inc., Pleasanton, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100694803","display_name":"Yu Chen","orcid":"https://orcid.org/0009-0000-5165-2912","observed_orcids":["https://orcid.org/0009-0000-5165-2912"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yu Chen","raw_affiliation_strings":["7Newave Pharmaceutical Inc., Pleasanton, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Newave Pharmaceutical Inc., Pleasanton, CA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5000921376","display_name":"John C. Byrd","orcid":"https://orcid.org/0000-0001-9830-0711","observed_orcids":["https://orcid.org/0000-0001-9830-0711"]},"institutions":[{"id":"https://openalex.org/I63135867","display_name":"University of Cincinnati","ror":"https://ror.org/01e3m7079","country_code":"US","type":"education","lineage":["https://openalex.org/I63135867"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John C. Byrd","raw_affiliation_strings":["8Department of Internal Medicine, University of Cincinnati, Cincinnati, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Department of Internal Medicine, University of Cincinnati, Cincinnati, OH","institution_ids":["https://openalex.org/I63135867"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"142","issue":"Supplement 1","first_page":"328","last_page":"328"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.8799999952316284},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9399999976158142},{"id":"https://openalex.org/keywords/relapsed-refractory-b-cell-malignancies","display_name":"relapsed/refractory B-cell malignancies","score":0.9779999852180481},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8629999756813049},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.5220000147819519}],"concepts":[{"id":"https://openalex.org/C180577832","wikidata":"https://www.wikidata.org/wiki/Q127920","display_name":"Covalent bond","level":2,"score":0.8020733594894409},{"id":"https://openalex.org/C90059517","wikidata":"https://www.wikidata.org/wiki/Q423572","display_name":"Bruton's tyrosine kinase","level":4,"score":0.5410626530647278},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.4319304823875427},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4268989861011505},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.289874404668808},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17277565598487854},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.08822891116142273},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0831516683101654}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2023-186432","doi":"https://doi.org/10.1182/blood-2023-186432","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-186432","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389220418","https://openalex.org/W4405045608","https://openalex.org/W4417001880","https://openalex.org/W4389242990","https://openalex.org/W4389234169","https://openalex.org/W4399480880","https://openalex.org/W7162669704","https://openalex.org/W4389231314","https://openalex.org/W4389222063","https://openalex.org/W2983711926"],"abstract_inverted_index":{"Introduction:":[0],"Inhibitors":[1],"of":[2,42,73,116,130,135,152,166,269,320,351,363,383,394,407,452,463,485],"Bruton's":[3],"Tyrosine":[4],"Kinase":[5],"(BTKi)":[6],"have":[7,63,178,314,415,438,444],"been":[8,64,439,445,522,622],"transformative":[9],"therapies":[10],"in":[11,46,89,169,287,308,450,474,482,493,499,531,625,643],"chronic":[12],"lymphocytic":[13],"leukemia":[14],"(CLL)":[15],"and":[16,34,60,79,83,145,279,303,389,441,461,472,513,534,577,583,659,668,701],"other":[17],"lymphoid":[18],"malignancies.":[19,174],"Despite":[20],"extended":[21],"remissions,":[22],"most":[23,118,442],"patients":[24],"(pts)":[25],"will":[26,663,688,704],"relapse.":[27],"Covalent":[28],"BTKi":[29,49,371],"(cBTKi)":[30],"including":[31,238,328,372,648],"ibrutinib,":[32],"acalabrutinib,":[33],"zanubrutinib,":[35],"share":[36],"a":[37,43,68,131,159,267,276,281,494],"common":[38,119],"resistance":[39,120],"mechanism,":[40],"acquisition":[41],"C481":[44,388],"mutation":[45,307],"BTK.":[47],"Non-covalent":[48],"(ncBTKi)":[50],"can":[51,76],"overcome":[52],"this,":[53],"however,":[54],"second-site":[55],"mutations,":[56,62,294],"notably":[57],"T474":[58,301,390],"gatekeeper":[59,298,692],"kinase-dead":[61],"observed.":[65],"LP-168":[66,167,620],"is":[67,100,158,588],"selective":[69],"next":[70],"generation":[71],"inhibitor":[72],"BTK":[74,81,109,293,387,586],"that":[75,595],"bind":[77],"wild-type":[78,108],"C481-mutated":[80],"covalently":[82],"non-covalently,":[84],"respectively,":[85],"with":[86,107,137,154,171,190,240,273,317,342,385,413,547,564,598,628,651,691],"preclinical":[87],"activity":[88,99,112],"resistant":[90],"CLL":[91,175,264,414,646],"models":[92],"(submitted":[93],"to":[94,102,229,489,509,608,635,678,694],"ASH":[95],"2023).":[96],"This":[97],"dual":[98],"hypothesized":[101],"allow":[103],"efficacy":[104,146,640,702],"against":[105],"cells":[106],"through":[110,122],"covalent":[111],"while":[113],"preventing":[114],"expansion":[115,191,662],"the":[117,150,361,381,405,417,673,680,708],"mechanisms":[121],"non-covalent":[123],"activity.":[124],"Here":[125],"we":[126],"describe":[127],"initial":[128],"results":[129],"phase":[132,161,682],"1":[133,162,475,487,532,535],"study":[134,165,418],"LP-168,":[136],"safety":[138,222],"evaluation":[139,147],"focusing":[140,148],"on":[141,149],"DLT":[142,426,437,503],"evaluable":[143,427,433],"pts,":[144,484,647],"cohort":[151,687],"pts":[153,170,176,235,265,284,290,296,305,313,348,364,384,412,428,453,690],"CLL.":[155],"Methods:":[156],"NCT04775745":[157],"multicenter":[160],"dose":[163,214,219,330,374,593,661],"escalation":[164,184,215],"monotherapy":[168],"relapsed/refractory":[172],"B-cell":[173],"must":[177],"received":[179,266,367],"\u22652":[180],"prior":[181,271,277,370],"therapies.":[182],"Dose":[183],"was":[185,216,332,357,377,401,504,529,560,570,580,641],"performed":[186],"using":[187,209],"3+3":[188],"design":[189],"at":[192,242,300,349,392,506,574,590,592,611,632,665,707],"multiple":[193],"doses.":[194,549],"Treatment":[195],"emergent":[196],"adverse":[197],"events":[198],"(TEAEs)":[199],"were":[200,207,236,259,335,432,480,596],"assessed":[201],"per":[202],"NCI":[203],"CTCAE":[204],"v5.0.":[205],"Responses":[206],"evaluated":[208],"iwCLL":[210],"2018":[211],"criteria.":[212],"Intra-patient":[213],"permitted":[217],"when":[218],"levels":[220,331,594],"cleared":[221],"evaluation.":[223],"Results:":[224],"From":[225],"16":[226],"Sep":[227],"2021":[228],"10":[230,261],"Jul":[231,262],"2023,":[232],"43":[233,425],"DLT-evaluable":[234],"enrolled,":[237],"35":[239],"CLL,":[241],"doses":[243,350,393,507,576,633],"from":[244],"100-300":[245],"mg":[246,252,353,511,515,616,637,667,670],"daily":[247,512,671],"as":[248,250],"well":[249,623],"150":[251,514],"twice":[253,516],"daily.":[254,517,618,638],"Data":[255],"for":[256,419,434],"this":[257,408,626],"abstract":[258],"locked":[260],"2023.":[263],"median":[268,318],"3":[270,466,526],"therapies,":[272],"94%":[274],"receiving":[275],"cBTKi":[278],"11%":[280],"ncBTKi.":[282],"20":[283],"had":[285,291,297,306,366],"alterations":[286],"TP53,":[288],"21":[289],"C481S":[292],"7":[295],"mutations":[299,391,693],"BTK,":[302],"5":[304,411],"PLC":[309],"\u03b32":[310],"(Table).":[311],"33":[312],"response":[315,325,337,341],"data":[316,423,703],"follow-up":[319],"12.6":[321],"months":[322],"(Figure).":[323],"Overall":[324],"rate":[326],"(ORR)":[327],"all":[329,373,430,575],"54.5%":[333],"(18/33)-all":[334],"partial":[336,340],"(PR)":[338],"or":[339,354,397,467,527,614,653],"lymphocytosis":[343],"(PR-L).":[344],"When":[345],"evaluating":[346],"only":[347,368,410],"200":[352,613,666],"higher,":[355],"ORR":[356,376,400],"66.7%":[358],"(10/15).":[359],"In":[360,380],"subgroup":[362,382],"who":[365],"one":[369,652],"levels,":[375],"77.8%":[378],"(14/18).":[379],"both":[386],"150mg":[395],"BID":[396],"300mg":[398],"QD,":[399],"75%":[402],"(3/4).":[403],"At":[404,422],"time":[406],"report,":[409],"discontinued":[416],"progressive":[420],"disease.":[421],"lock,":[424],"(with":[429],"histologies)":[431],"safety.":[435],"No":[436,502,518],"observed,":[440],"AE":[443,469,479,542],"low":[446],"grade.":[447],"TEAE":[448],"seen":[449,481,530],">20%":[451],"included":[454,470],"diarrhea,":[455],"fatigue,":[456],"arthralgia,":[457],"headache,":[458],"constipation,":[459],"cough,":[460],"dizziness;":[462],"those,":[464],"grade":[465,525],"higher":[468,528],"fatigue":[471],"constipation":[473],"pt":[476,498,536],"each.":[477],"Serious":[478],"11":[483],"which":[486],"led":[488],"discontinuation":[490],"(intracranial":[491],"hemorrhage":[492],"mantle":[495],"cell":[496],"lymphoma":[497],"complete":[500],"remission).":[501],"identified":[505,631],"up":[508,634],"300":[510,615,636,669],"atrial":[519],"fibrillation/flutter":[520],"has":[521,621],"reported.":[523],"Hypertension":[524],"pt,":[533],"experienced":[537],"high-grade":[538],"bleeding":[539],"(as":[540],"described).":[541],"frequency":[543],"did":[544],"not":[545],"increase":[546],"increasing":[548],"Pharmacokinetics":[550],"showed":[551],"plasma":[552],"exposure":[553],"increases":[554],"dose-dependently.":[555],"Steady":[556,567],"state":[557,568],"AUC":[558],"24h":[559],"between":[561,571,581],"47.1-94.6":[562],"ug/mL*h":[563],"limited":[565],"accumulation.":[566],"half-life":[569],"15.3-21.9":[572],"hours":[573],"C":[578],"max":[579],"3500":[582],"5600":[584],"ng/mL.":[585],"occupancy":[587],"nearly":[589],"100%":[591],"tested,":[597],"little":[599],"variability":[600],"among":[601],"pts.":[602],"Collective":[603],"review":[604],"demonstrates":[605],"optimal":[606],"Cmax":[607],"be":[609,705],"achieved":[610],"either":[612],"dosed":[617],"Conclusions:":[619],"tolerated":[624],"study,":[627],"no":[629],"DLTs":[630],"Preliminary":[639],"observed":[642],"high":[644],"risk":[645],"those":[649],"treated":[650],"more":[654],"BTKi.":[655],"Considering":[656],"safety,":[657,700],"efficacy,":[658],"PK/PD,":[660],"occur":[664],"following":[672],"FDA":[674],"Project":[675],"Optimus":[676],"guidelines":[677],"determine":[679],"recommended":[681],"2":[683],"dose.":[684],"A":[685],"separate":[686],"enroll":[689],"further":[695],"explore":[696],"efficacy.":[697],"Updated":[698],"biomarker,":[699],"presented":[706],"meeting.":[709]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-12-02T00:00:00"}